Table 2.
Standardized Incidence Ratios of Group A vs Group B, Showing Analysis of Population-Based vs Clinic-Based Families
| Group A (MSI-H) SIR (95% CI)* | Group B (MSI-L/MSS) SIR (95% CI)* | P Value† | ||||
|---|---|---|---|---|---|---|
| Tumor Site | Population-Based (n = 1052)‡ |
Clinic-Based (n = 803)‡ |
Population-Based (n = 976)‡ |
Clinic-Based (n = 591)‡ |
Population-Based or Unselected |
Clinic- Based |
| Colorectum | 4.3 (3.4–5.3)§ | 9.6 (7.5–12.3)§ | 2.0 (1.3–2.7)§ | 3.1 (1.9–4.3)§ | <.001 | <.001 |
| Uterus | 3.4 (1.9–4.8)§ | 5.4 (3.1–7.9)§ | 0.6 (0.0–1.5) | 1.1 (0.0–2.6) | .001 | .002 |
| Stomach | 3.3 (1.4–5.4)§ | 7.1 (3.1–11.7)§ | 1.7 (0.4–3.5) | 0.8 (0.0–2.6) | .25 | .007 |
| Breast | 0.4 (0.2–0.6) | 0.6 (0.3–1.0) | 0.5 (0.2–0.8) | 0.2 (0.0–0.5) | .68 | .15 |
| Kidney | 1.8 (0.5–3.3) | 4.1 (1.5–7.1)§ | 1.0 (0.0–2.2) | 0.6 (0.0–2.1) | .36 | .03 |
| Lung | 0.2 (0.0–0.4) | 0.6 (0.2–1.1) | 0.3 (0.1–0.5) | 0.2 (0.0–0.5) | .69 | .19 |
| Ovary | 1.6 (0.5–3.1) | 2.6 (0.8–5.1) | 1.4 (0.3–3.0) | 1.8 (0.0–4.0) | .84 | .60 |
| Hematopoietic | 0.7 (0.2–1.1) | 0.3 (0.0–0.7) | 0.2 (0.0–0.5) | 0.5 (0.0–1.1) | .07 | .47 |
| Pancreas | 2.1 (0.8–3.8) | 1.0 (0.0–2.7) | 0.3 (0.0–1.1) | 0.6 (0.0–2.1) | .04 | .74 |
| Prostate | 0.3 (0.1–0.6) | 0.3 (0.0–0.7) | 0.1 (0.0–0.3) | 1.0 (0.3–1.8) | .17 | .09 |
| Small intestine | 9.7 (1.9–19.3)§ | 3.6 (0.0–12.0) | 2.5 (0.0–7.8) | NA‖ | .17 | .45 |
| Cervix | 0.2 (0.0–0.4) | 0.5 (0.0–0.9) | 0.1 (0.0–0.3) | 0.6 (0.1–1.3) | .67 | .65 |
| Bladder | 0.3 (0.0–0.7) | 0.8 (0.0–1.8) | NA‖ | 0.3 (0.0–1.1) | .21 | .46 |
| Liver | 0.9 (0.0–3.2) | 5.3 (0.0–11.7) | 1.1 (0.0–3.7) | NA‖ | .85 | .10 |
| Ureter | 10.0 (0.0–22.9) | 6.8 (0.0–21.8) | NA‖ | 8.7 (0.0–30.0) | .11 | .85 |
| Brain | 0.7 (0.0–1.9) | 0.6 (0.0–2.1) | NA‖ | 1.7 (0.0–4.2) | .19 | .43 |
| Head/neck | 0.4 (0.0–0.9) | NA‖ | 0.2 (0.0–0.5) | 0.7 (0.0–1.8) | .44 | .11 |
| Melanoma | 0.2 (0.0–0.6) | NA‖ | NA‖ | 0.3 (0.0–0.8) | .19 | .29 |
Abbreviations: CI, confidence interval; MSI-H, microsatellite instability–high; MSI-L, microsatellite instability–low; MSS, microsatellite stable; NA, not available; SIR, standardized incidence ratio.
SIRs and bootstrapped 95% CIs for cancers in first- and second-degree relatives of triad members fulfilling Amsterdam-I criteria, by microsatellite instability status as well as ascertainment mode.
Computed by comparing the SIR of the DNA mismatch repair groups (group A vs group B).
Number of first- and second-degree relatives, excluding triad members, included in the analysis.
Statistically significant estimate compared with the Surveillance, Epidemiology, and End Results population.9
Zero cancer events, so no bootstrap 95% CI was generated.